CJC-1295 vs Ipamorelin

CJC-1295 and ipamorelin are frequently used together in growth hormone (GH) secretagogue protocols, but they act through distinct receptors and produce different GH release kinetics. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog, while ipamorelin is a ghrelin receptor (GHSR1a) agonist. Their combination produces synergistic GH release exceeding either agent alone.

Mechanism of Action

CJC-1295: GHRH Analog

CJC-1295 is a synthetic analog of human GHRH(1-29) with D-Ala at position 2 and a tetrasubstituted Heza modification. It binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, activating the Gs-protein → adenylyl cyclase → cAMP → PKA pathway, stimulating GH gene transcription and exocytosis.

CJC-1295’s key modification is D-Ala2 substitution, which protects against DPP-IV enzymatic degradation. With Drug Affinity Complex (DAC) conjugation (CJC-1295-DAC), the peptide binds albumin, extending the half-life to approximately 6–8 days. Without DAC (CJC-1295 no-DAC), the half-life is approximately 30–40 minutes, requiring pulsatile dosing.

Ipamorelin: GHSR1a Agonist

Ipamorelin is a selective ghrelin receptor agonist that binds GHSR1a on somatotrophs, activating the Gq/PLC/IP₃/Ca²⁺ pathway. This triggers rapid GH vesicle release without stimulating new GH synthesis. Ipamorelin’s selectivity means it does not significantly elevate cortisol, ACTH, or prolactin.

Receptor and Signaling Comparison

Property	CJC-1295	Ipamorelin
Target receptor	GHRHR (Gs-coupled)	GHSR1a (Gq-coupled)
Second messenger	cAMP → PKA	IP₃/Ca²⁺ → PKC
GH effect	Transcription + release	Release only
Onset	Slow (hours)	Rapid (minutes)
Duration	Extended (DAC) or brief	Brief (~2 hrs)
Selectivity	High (GHRHR only)	High (GHSR1a only)
Cortisol effect	None	Minimal
ACTH effect	None	Minimal

GH Release Patterns

CJC-1295

CJC-1295 produces a sustained, moderate GH elevation:

• CJC-1295-DAC: GH elevation peaks at 4–6 hours post-injection, with sustained elevation over 24–48 hours
• CJC-1295 no-DAC: Transient GH pulse peaking at 15–30 minutes
• Pulsatility: Non-pulsatile with DAC (continuous exposure); pulsatile without DAC
• Peak GH levels: 15–30 ng/mL per pulse (no-DAC); 5–15 ng/mL sustained (DAC)

Ipamorelin

Ipamorelin produces discrete GH pulses mimicking physiological secretion:

• Pulse frequency: 6–8 pulses per 24 hours at standard dosing
• Pulse amplitude: 15–25 ng/mL per pulse
• Pulse duration: 1–2 hours
• Trough levels: Return to baseline between pulses
• Pattern: Most closely resembles natural nocturnal GH secretion

Combination: Synergistic Release

When combined, CJC-1295 and ipamorelin produce synergistic GH release exceeding the sum of individual effects:

• Mechanism: GHRH (CJC-1295) upregulates GH gene transcription and somatotroph sensitivity, while GHSR1a (ipamorelin) triggers rapid vesicle release
• Peak GH: 40–60 ng/mL (vs. 15–30 ng/mL for either alone)
• Duration: Extended GH elevation with pulsatile superimposition
• IGF-1 elevation: 50–100% above baseline (vs. 15–25% for either alone)

IGF-1 Elevation

Parameter	CJC-1295	Ipamorelin	Combination
Baseline IGF-1	Reference	Reference	Reference
Peak IGF-1 increase	20–35%	15–25%	50–100%
Time to peak IGF-1	24–48 hrs	12–24 hrs	24–48 hrs
Sustained elevation	Yes (DAC)	Moderate	High
Feedback suppression	Moderate	Minimal	Moderate

Half-Life and Dosing

CJC-1295

Formulation	Half-life	Dosing	Route
CJC-1295-DAC	6–8 days	30 µg/kg 1–2x/week	SC
CJC-1295 no-DAC	30–40 min	30–60 µg/kg 1–3x/day	SC

Ipamorelin

Dose	Half-life	Dosing	Route
200–300 µg	~2 hrs	2–3x daily	SC
100–200 µg	~2 hrs	1–2x daily	IV

Combination Protocols

Standard Protocol

Agent	Dose	Frequency	Timing
CJC-1295-DAC	30 µg/kg	2x/week	Morning
Ipamorelin	200 µg	2–3x/day	Pre-meal

Rationale for Combination

1. Dual receptor activation: GHRH + GHSR1a maximizes somatotroph stimulation
2. Complementary kinetics: CJC-1295 provides sustained GH pool; ipamorelin triggers pulsatile release
3. IGF-1 synergy: Higher IGF-1 elevation than monotherapy
4. Safety: Both agents are cortisol-neutral at therapeutic doses
5. Pulsatility preservation: Ipamorelin maintains pulse frequency despite CJC-1295 background elevation

Side Effect Profiles

CJC-1295

• Injection site reactions (redness, swelling)
• Headache (mild, transient)
• Facial flushing
• Possible fluid retention at high doses
• Theoretical concern: chronic GHRH stimulation may promote somatotroph hyperplasia (unconfirmed)

Ipamorelin

• Injection site reactions
• Mild headache
• No cortisol elevation
• No hypoglycemia at therapeutic doses
• Short-term use well-tolerated

Combination

• Generally well-tolerated
• Injection site reactions (summed)
• Headache may be more frequent
• No additive hormonal side effects

When to Choose Which

CJC-1295 monotherapy may be considered when:

• Sustained GH elevation is the goal
• GHRH receptor targeting is preferred
• Infrequent dosing is desired (DAC formulation)
• Combination with ipamorelin is not indicated

Ipamorelin monotherapy may be considered when:

• Pulsatile GH release is the goal
• Selectivity and cortisol neutrality are paramount
• Short-term or cycling use is planned
• Oral administration is not required

Combination therapy may be considered when:

• Maximum GH and IGF-1 elevation is the goal
• Synergistic effect is desired
• GHRH + GHSR1a dual activation is indicated
• Safety profile of both agents is acceptable

References

1. Ionescu M, et al. “Growth hormone-releasing peptide-2 (GHRP-2) and GHRH in healthy volunteers.” J Clin Endocrinol Metab 1998;83:3054-3060.
2. Teichman SL, et al. “A novel GHRH analogue (CJC-1295) produces sustained GH elevation.” J Clin Endocrinol Metab 2006;91:3478-3485.
3. Johansen PB, et al. “Ipamorelin: a novel GH secretagogue.” Eur J Endocrinol 2000;143:575-580.
4. Camillis JA, et al. “CJC-1295-DAC: pharmacokinetics and GH stimulation.” J Endocrinol Invest 2004;27:RC13-16.
5. Andersen AN, et al. “Growth hormone release from ipamorelin.” J Clin Endocrinol Metab 1995;80:2416-2421.